| Day I: Monday 16 November 2011 |
|
| 08:30 |
Conference registration |
| 09:00 |
Welcome |
| 09:10 |
Scope of the conference |
| 09:20 |
Setting the scene – Views from the European Parliament |
|
|
Session 1:
Introduction, Horizontal topics, General outline
|
|
|
| 09:30 |
What is Health Risk Assessment? What are the different disciplines contributing to this subject area? |
| 10:00 |
Fundamental physics of interaction – what are Electromagnetic Fields, how do they interact with body, what are the limits/restrictions? |
| 10:30 |
|
|
Exposure assessment, dosimetry –– what does it mean for the different types of studies?
Consists of 2 presentations |
| 10:50 |
1. Experimental studies |
| 11:20 |
2. Epidemiological studies |
|
|
Session 2:
The main sources of uncertainty in EMF health research and how they are addressed?
|
|
|
| 11:50 |
Introduction to the session: Are EMF special in generating uncertainty in the interpretation of research results? |
| 11:55 |
In epidemiology, Exposure-Dose |
| 12:25 |
In laboratory studies (in animal studies, in vitro studies and in human experimental studies) |
| 12:55 |
Discussion |
|
|
Session 3:
Current state of knowledge – Where are the areas of scientific consensus (consistency, coherence)
|
|
|
| 14:00 |
Introduction to the session |
|
Biological effects, basic mechanisms (not necessarily with an adverse health outcome), Interaction Mechanisms
|
| Consists of 2 presentations: |
| 14:05 |
1. ELF- Extremely Low Frequencies |
| 14:35 |
2. RF- Radio Frequencies |
|
Cancer and other long-term effects in humans, should consider time-trends versus case-control studies |
| Consists of 2 presentations |
| 15:05 |
1. LF (static fields, ELF, IF - Intermediate frequencies) |
| 15:35 |
2. RF |
| 16:15 |
Reproductive health |
| 16:45 |
Acute effects (e.g. nervous system effects: neurophysiological and neuropsychological, sleep) |
| 17:15 |
Self-reported symptoms |
| 17:45 |
Discussion on the scientific consensus |
|
|
| Day II: Monday 16 November 2011 |
|
|
|
Session 4:
What are the areas of scientific inconsistency and knowledge gaps?
|
|
|
| 08:30 |
Introduction to the session |
|
Biological effects, basic mechanisms (not necessarily with an adverse health outcome), Interaction Mechanisms |
| 2 presentations: |
| 08:35 |
1) ELF |
| 09:05 |
2) RF |
|
Cancer and other long-term effects in humans, should consider time-trends versus case-control studies, possibly address etiology of brain cancer more generally mention differences in results between different meta analyses, focus on RF (2 presentations ): |
| 09:35 |
1) RF 1 |
| 10:05 |
2) RF 2 |
| 10:35 |
|
| 10:55 |
Neurodegenerative (ELF) |
| 11:25 |
Acute effects (e.g. nervous system effects: neurophysiological and neuropsychological, sleep) |
| 11:55 |
Overview of new technologies |
| 12:15 |
Other frequency fields, Changing exposure scenarios / changing and new technologies |
| 12:35 |
Discussion on the inconsistencies, knowledge gaps |
|
|
Session 5:
Lessons learned and recommendations for the future
|
|
|
| 14:00 |
Introduction |
| 14:10-15:40 |
Panel Discussion to help draw conclusions and provide outlook in particular on: |
|
1) Feedback on sessions 3 and 4 – Differences in opinion? Research priorities? |
|
2) Will certain uncertainties ever be clarified? What is your experience on this from your research perspective? |
|
3) What new questions might need answering considering changes in exposure and technologies? |
|
4) Assessment of research priorities? |
| 15:40 |
General Discussion |
| 16:30 |
Conclusions |
|
1) Based on results of conferences, are ongoing research programmes sufficient to address knowledge gaps identified? |
|
2) How to prioritize research |
| a) From the point of view of Public Health? Which criteria to use? |
| b) From the point of view of Occupational Health? |
|
3) What’s next? Rapporteurs reports, EC actions. Reports freely available. |
| 16:50- 17:00 |
Closing remarks (European Commission, SCENIHR - Scientific Committee on Emerging and Newly Identified Health Risks) |
